Chinese expert consensus on clinical drug prevention and treatment of osteonecrosis of the femoral head（2023)

Original Article | Vol 3 | Issue 2 |  July-December 2023 | page: 22-28 | Wei Sun , Fuqiang Gao , Zirong Li , Xu Yang , Jike Lu

DOI: https://doi.org/10.13107/jrs.2023.v03.i02.95

Author: Wei Sun , Fuqiang Gao , Zirong Li , Xu Yang , Jike Lu

[1] Centre for Osteonecrosis and Joint-Preserving & Reconstruction, Department of Orthopedics, China-Japan Friendship Hospital, Beijing 100029, China.
[2] Department of Orthopaedic Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Address of Correspondence
Dr. Wei Sun,
Centre for Osteonecrosis and Joint-Preserving & Reconstruction, Department
of Orthopedics, China-Japan Friendship Hospital, Beijing 100029, China.
E-mail: wei.sun@pennmedicine.upenn.edu

Abstract

The in-depth understanding of osteonecrosis of the femoral head (ONFH), has lead more and more patients to seek for medical treatment in the early stage of the disease. Surgical treatment of femoral head necrosis alone is no longer sufficient for the current patients’ demand. The rational and effective use of drugs to strengthen the prevention and early treatment of femoral head necrosis delaying the progression of the disease, is becoming more and more important. This article combines the latest expert consensus and evidence-based medical research on the principles of ONFH diagnosis and treatment according to Chinese and Western medicine and is organized by Chinese experts from the Association Related to Osseous Circulation and the Chinese Microcirculation Society (CSM-ARCO). This consensus was formulated with focus on drug types, characteristics, and safety. Rationality and consideration of basic principles of drug use will provide safe, reasonable, standardized, and effective drug use in medical institutions at all levels. This consensus is only an expert guideline based on literature and clinical experience, not a requirement for mandatory implementation. The clinical practice can be tailored to the actual local conditions to develop appropriate prevention and treatment measures for patients.
Keywords: Osteonecrosis of the femoral head; Expert consensus; Drug prevention and treatment

References:

[1] Sun W. The etiology, pathology and pathogenesis of osteonecrosis of the femoral head. Chinese Journal of General Practitioners, 2006, (02): 75-7. In Chinese.
[2] Cui L., Zhuang Q., Lin J., et al. Multicentric epidemiologic study on six thousand three hundred and ninety five cases of femoral head osteonecrosis in China. Int Orthop, 2016, 40(2): 267-76.
[3] van den Heuvel-Eibrink M. M., Pieters R. Steroids and risk of osteonecrosis in ALL: take a break. The Lancet Oncology, 2012, 13(9): 855-7.
[4] Li ZR. Clinical diagnosis and treatment of osteonecrosis of the femoral head (2015 edition). Chinese Journal of Joint Surgery (Electronic Edition), 2015, 9(01): 133-8. In Chinese.
[5] Chinese guidelines for clinical diagnosis and treatment of osteonecrosis of the femoral head in adults (2020). Chinese Journal of Orthopaedics, 2020, 40(20): 1365-76. In Chinese.
[6] Wei QS, Yang F, Chen XJ, et al. Microarchitecture features and pathology of necrotic region in patients with steroid-induced and alcohol-induced osteonecrosis of femoral head. Chinese Journal of Rehabilitation and Reconstructive Surgery, 2018, 32(07): 866- 72. In Chinese.
[7] Expert consensus on the criteria for the diagnosis and treatment of adult femoral head necrosis (2012). Chinese Journal of Bone and Joint Surgery, 2012, 5(02): 188-95. In Chinese.
[8] Chinese guideline for the diagnosis and treatment of osteonecrosis of the femoral head (2016). Chinese Journal of Orthopaedics, 2016, 36(15): 945-54. In Chinese.
[9] Yoon B. H., Mont M. A., Koo K. H., et al. The 2019 Revised Version of Association Research Circulation Osseous Staging System of Osteonecrosis of the Femoral Head. J Arthroplasty, 2020, 35(4): 933-40.
[10] Glueck C. J., Freiberg R. A., Wang P. Treatment of Osteonecrosis of the Hip and Knee with Enoxaparin. Osteonecrosis. 2014: 241-7.
[11] Guo P., Gao F., Wang Y., et al. The use of anticoagulants for prevention and treatment of osteonecrosis of the femoral head: A systematic review. Medicine (Baltimore), 2017, 96(16): e6646.
[12] Liu B. Y., Yang L., Wang B. J., et al. Prevention for glucocorticoid-induced osteonecrosis of femoral head: a long-term clinical follow-up trail. Zhonghua yi xue za zhi, 2017, 97(41): 3213-8. In Chinese.
[13] Albers A., Carli A., Routy B., et al. Treatment with acetylsalicylic acid prevents short to mid-term radiographic progression of nontraumatic osteonecrosis of the femoral head: a pilot study. Canadian journal of surgery Journal canadien de chirurgie, 2015, 58(3): 198-205.
[14] Cao H., Guan H., Lai Y., et al. Review of various treatment options and potential therapies for osteonecrosis of the femoral head. Journal of orthopaedic translation, 2016, 4: 57-70.
[15] Mont M. A., Salem H. S., Piuzzi N. S., et al. Nontraumatic Osteonecrosis of the Femoral Head: Where Do We Stand Today?: A 5-Year Update. The Journal of bone and joint surgery American volume, 2020, 102(12): 1084-99.
[16] Guo P., Gao F., Wang Y., et al. The use of anticoagulants for prevention and treatment of osteonecrosis of the femoral head: A systematic review. 2017, 96(16): e6646.
[17] Albers A., Carli A., Routy B., et al. Treatment with acetylsalicylic acid prevents short to mid-term radiographic progression of nontraumatic osteonecrosis of the femoral head: a pilot study. 2015, 58(3): 198-205.
[18] Wang W., Zhang N., Guo W., et al. Combined pharmacotherapy for osteonecrosis of the femoral head after severe acute respiratory syndrome and interstitial pneumonia: two and a half to fourteen year follow-up. 2018, 42(7): 1551-6.
[19] Li D., Yang Z., Wei Z., et al. Efficacy of bisphosphonates in the treatment of femoral head osteonecrosis: A PRISMA-compliant meta-analysis of animal studies and clinical trials. 2018, 8(1): 1450.
[20] Hong Y. C., Luo R. B., Lin T., et al. Efficacy of alendronate for preventing collapse of femoral head in adult patients with nontraumatic osteonecrosis. Biomed Res Int, 2014, 2014: 716538.
[21] Ramachandran M., Ward K., Brown R. R., et al. Intravenous bisphosphonate therapy for traumatic osteonecrosis of the femoral head in adolescents. The Journal of bone and joint surgery American volume, 2007, 89(8): 1727-34.
[22] Yuan H. F., Guo C. A., Yan Z. Q. The use of bisphosphonate in the treatment of osteonecrosis of the femoral head: a meta-analysis of randomized control trials. Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2016, 27(1): 295-9.
[23] Tong PJ, Xiao LW, Ji WF, et al. Research on the role of metabolism of fatty substance and osteoclast activity during the development of steroid-induced necrosis of femoral head. China Journal of Orthopaedics and Traumatology, 2009, 22 (02): 110-3. In Chinese.
[24] Pritchett J. W. Statin therapy decreases the risk of osteonecrosis in patients receiving steroids. Clinical orthopaedics and related research, 2001, (386): 173-8.
[25] Kandil A., Cui Q. Lipid-lowering agents and their effects on osteonecrosis: Pros and cons. Osteonecrosis. 2014: 255-9.
[26] Li Z. R., Cheng L. M., Wang K. Z., et al. Herbal Fufang Xian Ling Gu Bao prevents corticosteroid-induced osteonecrosis of the femoral head-A first multicentre, randomised, double-blind, placebo-controlled clinical trial. Journal of orthopaedic translation, 2018, 12: 36-44.
[27] Huang Z., Fu F., Ye H., et al. Chinese herbal Huo-Gu formula for the treatment of steroid-associated osteonecrosis of femoral head: A 14-year follow-up of convalescent SARS patients. Journal of orthopaedic translation, 2020, 23: 122-31.
[28] Leucht P., Goodman S. B. Is there a role for BMPs in the treatment of osteonecrosis?. Osteonecrosis. 2014: 261-4.
[29] Sun W., Li Z., Gao F., et al. Recombinant human bone morphogenetic protein-2 in debridement and impacted bone graft for the treatment of femoral head osteonecrosis. 2014, 9(6): e100424.
[30] Vandermeer J., Kamiya N., Aya-ay J., et al. Local administration of ibandronate and bone morphogenetic protein-2 after ischemic osteonecrosis of the immature femoral head: a combined therapy that stimulates bone formation and decreases femoral head deformity. 2011, 93(10): 905-13.
[31] Drescher W., Knobe M., Wagner W., et al. New therapies of bone necrosis. Osteonecrosis. 2014: 273-5.
[32] Xu Y., Jiang Y., Xia C., et al. Stem cell therapy for osteonecrosis of femoral head: Opportunities and challenges. 2020, 15: 295-304.
[33] Lee H. S., Huang G. T., Chiang H., et al. Multipotential mesenchymal stem cells from femoral bone marrow near the site of osteonecrosis. Stem cells (Dayton, Ohio), 2003, 21(2): 190-9.
[34] Li C., Li G., Liu M., et al. Paracrine effect of inflammatory cytokine-activated bone marrow mesenchymal stem cells and its role in osteoblast function. 2016, 121(2): 213-9.
[35] Haumer A., Bourgine P., Occhetta P., et al. Delivery of cellular factors to regulate bone healing. 2018, 129: 285-94.
[36] Mao L., Jiang P., Lei X., et al. Efficacy and safety of stem cell therapy for the early-stage osteonecrosis of femoral head: a systematic review and meta-analysis of randomized controlled trials. Stem Cell Res Ther, 2020, 11(1): 445.
[37] Han J., Gao F., Li Y., et al. The Use of Platelet-Rich Plasma for the Treatment of Osteonecrosis of the Femoral Head: A Systematic Review. Biomed Res Int, 2020, 2020: 2642439.
[38] Liu GH, Ji WB, Liu JT, et al. Clinical observation of Yishen Huoxue decoction (YSHXD) for the treatment of non-traumatic osteonecrosis of femoral head at early and middle stage. China Journal of Orthopaedics and Traumatology, 2019, 32 (11): 1003-7. In Chinese.
[39] Sung P., Yang Y., Chiang H., et al. Cardiovascular and Cerebrovascular Events Are Associated With Nontraumatic Osteonecrosis of the Femoral Head. 2018, 476(4): 865-74.
[40] Emkey R., Delmas P. D., Bolognese M., et al. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. Clin Ther, 2009, 31(4): 751-61.
[41] Teng J, Wang D, Xu X, et al. Surveying the status of older patients’ multiple-drug- using behavior and studying on the clinical strategies of co-morbidity management. The Chinese Health Service Management, 2015, 32(09): 695-7. In Chinese.
[42] Sodhi N., Acuna A., Etcheson J., et al. Management of osteonecrosis of the femoral head. 2020: 122-8.

[Full Text HTML] [Full Text PDF]